Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 23 March 2006. doi:10.1136/jcp.2005.033100
Journal of Clinical Pathology 2006;59:912-915
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

ORIGINAL ARTICLE

Furosemide reverses multidrug resistance status in bladder cancer cells in vitro

A G Speers1, B A Lwaleed2, J M Featherstone2, B J Sallis1 and A J Cooper1

1 Department of Biomedical Sciences, University of Portsmouth, Portsmouth, UK
2 Department of Urology, Southampton University Hospitals NHS Trust, Southampton, UK

Correspondence to:
Correspondence to:
B A Lwaleed
Department of Urology, Central block, Level E, West Wing, Mailpoint 67, Southampton University Hospitals NHS Trust, Tremona Road, Southampton, SO16 6YD, UK; bashir{at}soton.ac.uk

Background: Multidrug resistance (MDR) has a potentially serious influence on cancer treatment and should be taken into consideration in the design and application of therapeutic regimens. It is mediated through the activity of cellular pumps.

Aim: To investigate whether furosemide, itself a pump-blocker, reverses MDR in an in vitro model.

Materials and methods: An MDR bladder cancer cell line (MGH-u 1R) and its parental (drug sensitive) clone were exposed to epirubicin and furosemide, with the concentration of one drug fixed and that of the other serially diluted in a 96-well plate format. Both drugs formed the variable component in separate experiments. After a 1-h exposure, the cells were washed and replenished with fresh medium. To examine the toxicity of epirubicin and furosemide separately and in combination, monotetrazolium-based assays were carried out. Intracellular epirubicin distribution was assessed by confocal microscopy as a second index of resistance status after in vitro exposure.

Results: MGH-u 1R cells incubated with furosemide showed distribution of drug similar to that in the parental cells (MGH-u 1 sensitive). Controls (without furosemide) continued to show a resistant pattern of fluorescence. In cytotoxicity assays furosemide appeared substantially non-toxic. Resistant cells in the toxicity titration experiments showed increased resistance to levels of furosemide over 500 µg/ml. Parental cells were made only marginally more sensitive against increased background toxicity.

Conclusion: Furosemide is effective in reversing MDR status in bladder cancer cell lines in vitro. It may also have an increment of intrinsic cytotoxicity, but only at higher concentrations. We propose a potential for further investigation of furosemide as an adjunct to chemotherapy for superficial bladder cancer.

Abbreviations: ATP, adenosine triphosphate; MDR, multidrug resistance; MGH-u 1R, MDR bladder cancer cell line; P-gp, P-glycoprotein


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs